JAK/TYK2
Spondyloarthritis at ACR 2020: Dr. Lianne Gensler
San Francisco-based rheumatologist Dr. Lianne Gensler examines a wide range of spondyloarthritis topics at ACR 2020, including how to join up with others interested in spondyloarthritis; enthesitis; the utility of MRI for the diagnosis for axSpA; novel treatments; and the impact of drugs on disease modification.
Dr. Vibeke Strand previews ACR 2020 highlights, including The Great Debate
Dr. Vibeke Strand discusses opening day at ACR 2020, sessions she's looking forward, and provides a sneak peek into The Great Debate.
4 years ago
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 8.4 Years: An Updated Integrated Safety Analysis https://t.co/i456zSn6Ba #RA #Baricitinib #safety 13000 pt/yrs 8.4 yrs F/U no new safety signals VTE 0.5/100 pt yrs
4 years ago
Efficacy & Safety Deucravacitinib (BMS-986165), Oral, Selective TyK2 Inhib in Patients with Active PsA Results from a Phase 2, RDBPC Trial https://t.co/s3V5NtRpuW results-from-a-phase-2-randomized-double-blind-plac/ #psa #tyk2inhib Efficacy in PsA ?top of dose response
4 years ago
Tofacitinib for the Treatment of Adult Patients with Ankylosing Spondylitis: Primary Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study https://t.co/F86K1Lqou7 #tofacitinib #AS Tofa works in AS , zoster no VTE seen NNH 20(per SAE) NNT 2.5(per ASAS40)
4 years ago
The #ACR20 Great Debate will feature two experts discussing whether #JAK inhibitors should be used before biologics if methotrexate fails. The session runs Friday, Nov. 6., from 10:00 to 11:00 AM ET. Learn more → https://t.co/I8zTGn0Q06
There are some really interesting poster and abstract presentations on spondyloarthritis at the ACR Convergence 2020. I’ll be covering these topics, and discussing select individual posters and…
Axial Involvement in Psoriatic Arthritis: Dr. Eric Ruderman Perspective
Dr. Eric Ruderman, Chicago, IL., provides his perspective on ACR 2020 coverage of axial involvement in Psoriatic Arthritis. During his remarks, he discusses ACR abstracts #0344, #1372, #2025 and #0505.
Poster Hall